Vogt-Koyanagi-Harada Syndrome in a Canadian First Nations Population

References

• Du L, Kijlstra A, Yang P. Vogt-Koyanagi-Harada disease: novel insights into pathophysiology, diagnosis and treatment. Prog Retin Eye Res. 2016;52:84–111. doi:10.1016/j.preteyeres.2016.02.002.
   PubMed Web of Science ®Google Scholar
• Sukavatcharin S, Tsai JH, Rao NA. Vogt-Koyanagi-Harada disease in Hispanic Patients. Int Ophthalmol. 2007;27:143–148. doi:10.1007/s10792-006-9017-6.
   PubMedGoogle Scholar
• Ehmann D, Tennant MTS, Somani R, Rudnisky CJ. Vogt-Koyanagi-Harada disease in first nations and métis of Northern Alberta. Can J Ophthalmol. 2013;48(3):146–152. doi:10.1016/j.jcjo.2012.10.008.
   PubMed Web of Science ®Google Scholar
• Snyder DA, Tessler HH. Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol. 1980;90:69–75. doi:10.1016/S0002-9394(14)75078-0.
   PubMed Web of Science ®Google Scholar
• Martinez JA, Lopez PF, Sternberg P, et al. Vogt-Koyanagi-Harada syndrome in patients with Cherokee Indian ancestry. Am J Ophthalmol. 1992;114:615–620. doi:10.1016/S0002-9394(14)74493-9.
   PubMed Web of Science ®Google Scholar
• Davis JL, Kamal KM, Freidlin V, et al. HLA associations and ancestry in Vogt-Koyanagi-Harada disease and sympathetic ophthalmia. Ophthalmology. 1990;97:1137–1142. doi:10.1016/S0161-6420(90)32446-6.
   PubMed Web of Science ®Google Scholar
• Nussenblatt RB. Clinical studies of Vogt-Koyanagi-Harada’s disease at the National Eye Institute, NIH, USA. Jpn J Ophthalmol. 1988;32:330–333.
   PubMed Web of Science ®Google Scholar
• Levinson RD, See RF, Rajalingam R, et al. HLA-DRB1 and -DQB1 alleles in mestizo patients with Vogt-Koyanagi-Harada’s disease in Southern California. Hum Imm. 2004;65:1477–1482. doi:10.1016/j.humimm.2004.07.236.
   PubMed Web of Science ®Google Scholar
• Damico FM, da Silva FT, Gasparin F, Yamamoto JH. New insights into Vogt-Koyanagi-Harada disease. Arq Bras Oftalmol. 2009;72(3):413–420. doi:10.1590/S0004-27492009000300028.
   PubMed Web of Science ®Google Scholar
• Islam SMM, Numaga J, Matsuki K, et al. Influence of HLA-DRB1 gene variation on the clinical course of Vogt-Koyanagi-Harada Disease. Inv Ophthalmol Vis Sci. 1994;35(2):752–756.
   PubMed Web of Science ®Google Scholar
• Norose K, Yano A. Melanoma specific Th1 cytotoxic T lymphocyte lines in Vogt-Koyanagi-Harada disease. Br J Ophthalmol. 1996;80:1002–1008. doi:10.1136/bjo.80.11.1002.
   PubMed Web of Science ®Google Scholar
• Miserocchi E, Fogliato G, Modorati G, Bandello F. Review on the worldwide epidemiology of uveitis. Eur J Ophthalmol. 2013;23(5):705–717. doi:10.5301/ejo.5000278.
   PubMed Web of Science ®Google Scholar
• Roy M. Analysis of uveitis in a Canadian Aboriginal population. Can J Ophthalmol. 2014;49(2):128–134. doi:10.1016/j.jcjo.2013.09.020.
   PubMed Web of Science ®Google Scholar
• Statistics Canada. 2016 census [Internet]. Aboriginal peoples in Canada: Key results from the 2016 Census. 2017 Oct 25. Statistics Canada: Ottawa, Ont. https://www150.statcan.gc.ca/n1/daily-quotidien/171025/dq171025a-eng.htm. updated Jul 2, 2019; cited Jan 12 2020.
   Google Scholar
• Read RW, Holland GN, Rao NA, et al. Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature. Am J Ophthalmol. 2001;131(5):647–652. doi:10.1016/S0002-9394(01)00925-4.
   PubMed Web of Science ®Google Scholar
• Moorthy RS, Inomata H, Rao NA. Vogt-Koyanagi-Harada Syndrome. Surv Ophthalmol. 2001;131:647–652.
   Google Scholar
• Abu El-Asrar AM, Al Tamimi M, Hemachandran S, et al. Prognostic factors for clinical outcomes in patients with Vogt-Koyanagi-Harada disease treated with high-dose corticosteroids. Acta Ophthalmol. 2013;91:e486–e493. doi:10.1111/aos.12127.
   PubMed Web of Science ®Google Scholar
• Murthy SI, Moreker MR, Sangwan VS, et al. The spectrum of Vogt-Koyanagi-Harada disease in South India. Int Ophthalmol. 2007;27(2–3):131–136. doi:10.1007/s10792-007-9046-9.
   PubMedGoogle Scholar
• Rodriguez A, Calonge M, Pedroza-Seres M, et al. Referral patterns of uveitis in a tertiary eye care center. Arch Ophthalmol. 1996;114:593–599. doi:10.1001/archopht.1996.01100130585016.
   PubMed Web of Science ®Google Scholar
• Roy M. Relative prevalence of Aboriginal patients in a Canadian uveitic population. Can J Ophthalmol. 2012;47(2):185–188. doi:10.1016/j.jcjo.2012.01.026.
   PubMed Web of Science ®Google Scholar
• Paredes I, Ahmed M, Foster CS. Immunomodulatory therapy for Vogt-Koyanagi-Harada patients as first-line therapy. Ocul Immunol Inflamm. 2006;14:87–90. doi:10.1080/09273940500536766.
   PubMed Web of Science ®Google Scholar
• Shen E, Rathinam SR, Babu M, et al. Outcomes of Vogt-Koyanagi-Harada disease: a subanalysis from a randomized clinical trial of antimetabolite therapies. Am J Ophthalmol. 2017;168:279–286. doi:10.1016/j.ajo.2016.06.004.
   Web of Science ®Google Scholar
• Urzua CA, Velasquez V, Sabat P, et al. Earlier immunomodulatory treatment is associated with better visual outcomes in a subset of patients with Vogt-Koyanagi-Harada disease. Acta Ophthalmol. 2015;93:e475–e480. doi:10.1111/aos.12648.
   PubMed Web of Science ®Google Scholar
• Giordano VE, Schlaen A, Guzmán-Sánchez MJ, Couto C. Spectrum and visual outcomes of Vogt-Koyanagi-Harada disease in Argentina. Int J Ophthalmol. 2017;10:98–102.
   PubMed Web of Science ®Google Scholar
• Chee SP, Jap A, Bacsalexpand K. Prognostic factors of Vogt-Koyanagi-Harada disease in Singapore. Am J Ophthalmol. 2009;147(1):154–161. doi:10.1016/j.ajo.2008.07.044.
   PubMed Web of Science ®Google Scholar
• Arevalo JF, Lasave AF, Gupta V, et al. Clinical outcomes of patients with Vogt-Koyanagi-Harada disease over 12 years at a tertiary center. Ocul Immunol Inflamm. 2016;24:521–529. doi:10.3109/09273948.2015.1025984.
   PubMed Web of Science ®Google Scholar
• Yang P, Ren Y, Li B, Fang W, Meng Q, Kijlstra A. Clinical characteristics of Vogt-Koyanagi-Harada syndrome in Chinese patients. Ophthalmology. 2007;114:606–614. doi:10.1016/j.ophtha.2006.07.040.
   PubMed Web of Science ®Google Scholar
• Ohno S, Minakawa R, Matsuda H. Clinical studies of Vogt- Koyanagi-Harada’s disease. Jpn J Ophthalmol. 1988;32:334–343.
   PubMed Web of Science ®Google Scholar
• Hedayatfar A, Hosseini SM, Karimi N, et al. The spectrum of Vogt-Koyanagi-Harada disease in Iran. Int Ophthalmol. 2018;38:443–449. doi:10.1007/s10792-017-0478-6.
   PubMed Web of Science ®Google Scholar
• Mondkar SV, Biswas J, Ganesh SK. Analysis of 87 cases with Vogt- Koyanagi-Harada disease. Jpn J Ophthalmol. 2000;44:296–301.
   PubMed Web of Science ®Google Scholar
• Rao NA, Gupta A, Dustin L, et al. Frequency of distinguishing clinical features in Vogt-Koyanagi-Harada Disease. Ophthalmology. 2010;117(3):591–599. doi:10.1016/j.ophtha.2009.08.030.
   PubMed Web of Science ®Google Scholar
• Hopkins DM. The Bering Land Bridge. Redwood City (USA): Stanford University Press; 1967.
   Google Scholar
• Goldgeier MH, Klein LE, Klein-Angerer S, et al. The distribution of melanocytes in the leptomeninges of the human brain. J Investig Dermatol. 1984;82(3):235–238. doi:10.1111/1523-1747.ep12260111.
   PubMed Web of Science ®Google Scholar
• Sheriff F, Narayanan NS, Huttner AJ, Baehring JM. Vogt-Koyanagi-Harada Syndrome: a novel case and brief review of focal neurologic presentations. Neurol Neuroimmunol Neuroinflamm. 2014;1:1–3. doi:10.1212/NXI.0000000000000049.
   Google Scholar
• Qian Y, Glaser T, Esterberg E, Acharya NR. Depression and visual functioning in patients with ocular inflammatory disease. Am J Ophthalmol. 2012;153(2):370–378. doi:10.1016/j.ajo.2011.06.028.
   PubMed Web of Science ®Google Scholar
• Kirmayer LJ, Brass GM, Tait CL. The mental health of aboriginal peoples: transformations of identity and community. Can J Psychiatry. 2000;45:607–616. doi:10.1177/070674370004500702.
   PubMed Web of Science ®Google Scholar
• Wakefield D, Abu El-Asrar A, McCluskey P. Treatment of severe inflammatory eye disease in patients of reproductive age and during pregnancy. Ocul Immunol Inflamm. 2012;20:277–287. doi:10.3109/09273948.2012.684736.
   PubMed Web of Science ®Google Scholar